Association of Low Serum Levels of Apolipoprotein A-I With Adverse Outcomes in Patients With Nonischemic Heart Failure

Inamori, Masahiko; Obata, Jyun-ei; Abe, Makoto; Nakamura, Takamitsu; Kitta, Yoshinobu; Kodama, Yasushi; Kawabata, Ken‐ichi; Takano, Hajime; Fujioka, Daisuke; Saitō, Yukio; Kobayashi, Tsuyoshi; Hasebe, Hideyuki; Kugiyama, Kiyotaka

doi:10.1016/j.cardfail.2007.01.007

Cited by 44 publications

(40 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These seminal prospective data are in agreement with earlier cross-sectional studies showing that post-infarct ejection fraction is lower in patients with low HDL cholesterol levels (Kempen et al 1987;Wang et al 1998). Low HDL cholesterol levels and low levels of apolipoprotein (apo) A-I, the main apo of HDL, indicate an unfavourable prognosis in patients with heart failure independent of the aetiology (Iwaoka et al 2007;Mehra et al 2009). An intriguing observation is that apo A-I is expressed in the human heart and in the heart of human apo A-I transgenic mice (Baroukh et al 2004;Lowes et al 2006).…”

Section: Introductionsupporting

confidence: 87%

Therapeutic Potential of HDL in Cardioprotection and Tissue Repair

Linthout

Frias²,

Singh

et al. 2014

High Density Lipoproteins

View full text Add to dashboard Cite

Section: Introductionsupporting

confidence: 87%

Therapeutic Potential of HDL in Cardioprotection and Tissue Repair

Linthout

Frias²,

Singh

et al. 2014

High Density Lipoproteins

View full text Add to dashboard Cite

“…In contrast, Iwaoka et al [12] showed that low levels of apolipoprotein A-1 are independently associated with an adverse prognosis in patients with nonischemic HF. Several other studies [13,14,15,16,17] suggested that low total cholesterol levels are associated with increased mortality in patients with systolic nonischemic HF.…”

Section: Introductionmentioning

confidence: 99%

Low Levels of Low-Density Lipoprotein Cholesterol: A Negative Predictor of Survival in Elderly Patients with Advanced Heart Failure

Charach¹,

Rabinovich²,

Argov³

et al. 2013

Cardiology

View full text Add to dashboard Cite

Objectives: There are conflicting reports on the role of cholesterol as an adverse prognostic predictor in patients with heart failure (HF). This study aimed to examine the impact of low levels of low-density lipoprotein cholesterol (LDL-c) on cardiac mortality in a cohort of elderly patients with moderate and severe HF. Methods: Chronic HF patients from the HF Unit at the Tel-Aviv Medical Center (n = 212, 77% males) with an average NYHA classification of 2.8, a mean age of 76.9 ± 7.3 years (range 66-91) and a mean follow-up of 3.7 years were consecutively enrolled. The cohort was divided into tertiles according to LDL-c levels: LDL <90 mg/dl (group 1), LDL 90-115 mg/dl (group 2) and LDL >115 mg/dl (group 3). Results: The Cox regression analysis revealed that group 3 patients had the best outcome (p = 0.01 vs. groups 2 and 3), with 58% of them surviving longer than 50 months compared to 34% in group 1. The same trend was seen in the group of patients suffering from ischemic cardiomyopathy and in patients who were treated by statins (p = 0.04). Conclusion: Low LDL-c levels are associated with a reduced survival in elderly patients with clinically controlled moderate and severe HF.

show abstract

“…Various studies have already indicated that low Apo A-1 is an independent risk factor for CAD [23]. It is reported also to have a beneficial effect on non-ischemic heart failure through its anti-inflammatory effect [24]. It is also reported to be an early marker of CAD and may be helpful in the screening of younger patients [25].…”

Section: Introductionmentioning

confidence: 99%

Serum Apo A-1 and Its Role as a Biomarker of Coronary Artery Disease

Rahim

Abdullah

Ali

et al. 2016

Cureus

View full text Add to dashboard Cite

ObjectivesTo evaluate the role of apolipoprotein(Apo A-1) as a biomarker of coronary artery disease (CAD) and its comparison with the traditional marker high-density lipoprotein (HDL).MethodologyOne hundred patients proven to have coronary artery disease by angiography were recruited and their serum biomarkers were compared with 100 normal individuals adjusted for age and sex.ResultThe mean +/-standard deviation (SD) value of plasma Apo A-1 levels in the normal individuals were observed to be 207.42 +/- 41.35 (mg/dL) against 90.69 +/- 20.77 (mg/dL) in the cardiac patients. On the other hand the serum HDL levels were 52.93 +/-33.58 (mg/dL) in the normal individuals and 37.86 +/- 23.19 (mg/dL) in the cardiac patients. Both of these differences were statistically significant (p < 0.001). For Apo A-1, a large proportion of patients (85%) were found to be in the abnormal range when compared to the control group in which only 7% had an abnormal value. For HDL, a majority (70%) of the cardiac patients had abnormal values while 40% of the normal individuals also had abnormal values. The sensitivity of Apo A-1 for detecting CAD was 85%, while for HDL, it was only 69%. Similarly, the specificity of Apo A-1 for detecting CAD was 93%, while for HDL, it was 60%. When plotted on a receiver operating characteristic (ROC) curve, Apo A-1 had a much larger area under the curve when compared to HDL.ConclusionThis study suggests that Apo A-1 may, in fact, be more sensitive than HDL as a predictor of CAD. However, to completely elucidate its role as a biomarker, to set target serum levels and to increase its clinical use, further studies are required.

show abstract

Association of Low Serum Levels of Apolipoprotein A-I With Adverse Outcomes in Patients With Nonischemic Heart Failure

Cited by 44 publications

References 21 publications

Therapeutic Potential of HDL in Cardioprotection and Tissue Repair

Therapeutic Potential of HDL in Cardioprotection and Tissue Repair

Low Levels of Low-Density Lipoprotein Cholesterol: A Negative Predictor of Survival in Elderly Patients with Advanced Heart Failure

Serum Apo A-1 and Its Role as a Biomarker of Coronary Artery Disease

Contact Info

Product

Resources

About